MARKET NEWS

Cytovation Initiates Clinical Development Program for First-in-Class Agent for Tumor Immunotherapy
NapaJen Pharma & Astellas Pharma Establish Research Collaboration for Discovery & Development of Novel Oligonucleotides
Innovate Biopharmaceuticals Reports Financing to Initiate Phase 3 Clinical Trial
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis
BioAegis Therapeutics Completes Enrollment in Phase 1b/2a Dose-Ranging Safety Study
Altimmune Announces Positive Results From NasoVAX Extension Study

  FEATURED EDITORIAL

  COMPANY PROFILE

Credence MedSystems is setting a new standard in drug delivery, helping you differentiate your products through innovative delivery systems while preserving your trusted processes. Simple, safe, and intuitive usability creates a better, safer experience for patients and healthcare professionals. Innovative designs provide safety activation clicks, end-of-dose feedback cues, and automatic needle retraction—without changes to familiar injection procedures. Our unique product innovations coexist with your existing processes, avoiding disruption to your filling lines and simplifying your secondary packaging operations. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Enterome Announces Research Collaboration With Dana-Farber Cancer Institute

Enterome Announces Research Collaboration With Dana-Farber Cancer Institute

Enterome recently announced it has entered into a research and development collaboration with Dana-Farber Cancer Institute to evaluate and develop gut microbiome-derived antigens as potential cancer immunotherapies.

Amphastar Pharmaceuticals Receives ANDA Approval for Multi Dose Vial Drug

Amphastar Pharmaceuticals Receives ANDA Approval for Multi Dose Vial Drug

Amphastar Pharmaceuticals, Inc. recently announced the US FDA granted approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection 300 mg/3 mL (100 mg/mL) Multiple Dose Vial (MDV).

Aptar Pharma’s Nasal Device Approved by FDA for Breakthrough Treatment

Aptar Pharma’s Nasal Device Approved by FDA for Breakthrough Treatment

Aptar Pharma recently announce that its Bidose nasal spray device was recently approved by the US FDA for a breakthrough therapy in the field of depression.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 3 – Poymers & Biomaterials
April 10 – Excipients